相似文献
1
COVID-19 vaccination: Why extend the interval between doses?
J Assoc Med Microbiol Infect Dis Can. 2021 Mar 25;6(2):73-78. doi: 10.3138/jammi-2021-0323. eCollection 2021 Jun.
2
Summary of the NACI Update on Herpes Zoster Vaccines.
Can Commun Dis Rep. 2018 Sep 6;44(9):220-225. doi: 10.14745/ccdr.v44i09a06.
3
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2022-2023.
Can Commun Dis Rep. 2022 Sep 1;48(9):373-382.
4
Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2016-2017.
Can Commun Dis Rep. 2016 Sep 1;42(9):188-192. doi: 10.14745/ccdr.v42i09a06.
5
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2021-2022.
Can Commun Dis Rep. 2021 Sep 10;47(9):372-380. doi: 10.14745/ccdr.v47i09a04.
6
Summary of the NACI Seasonal Influenza Vaccine Statement for 2018-2019.
Can Commun Dis Rep. 2018 Jun 7;44(6):123-128. doi: 10.14745/ccdr.v44i06a01.
7
Summary of the NACI Seasonal Influenza Vaccine Statement for 2020-2021.
Can Commun Dis Rep. 2020 May 7;46(5):132-137. doi: 10.14745/ccdr.v46i05a06.
8
Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015-2016.
Can Commun Dis Rep. 2015 Oct 1;41(10):227-232. doi: 10.14745/ccdr.v41i10a02.
9
Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization.
Vaccine. 2010 Apr 19;28 Suppl 1:A58-63. doi: 10.1016/j.vaccine.2010.02.035.
10
Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017-2018.
Can Commun Dis Rep. 2017 May 4;43(5):96-103. doi: 10.14745/ccdr.v43i05a03.
引用本文的文献
1
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations.
Nat Commun. 2025 Jun 5;16(1):5219. doi: 10.1038/s41467-025-60216-3.
2
The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.
Front Immunol. 2024 Feb 16;15:1330549. doi: 10.3389/fimmu.2024.1330549. eCollection 2024.
3
Third booster vaccination and stopping the Omicron, a new variant of concern.
Vacunas. 2022 Sep-Dec;23:S103-S110. doi: 10.1016/j.vacun.2022.05.005. Epub 2022 Jul 7.
4
A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021.
Microbiol Spectr. 2022 Jun 29;10(3):e0113422. doi: 10.1128/spectrum.01134-22. Epub 2022 Jun 2.
5
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
Microbiol Spectr. 2022 Feb 23;10(1):e0256321. doi: 10.1128/spectrum.02563-21.
6
SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Microbiol Spectr. 2022 Feb 23;10(1):e0226221. doi: 10.1128/spectrum.02262-21. Epub 2022 Feb 16.
7
COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in March 2021.
Can Commun Dis Rep. 2021 Dec 9;47(12):543-552. doi: 10.14745/ccdr.v47i12a05.
8
Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
Indian J Med Microbiol. 2021 Oct-Dec;39(4):417-422. doi: 10.1016/j.ijmmb.2021.08.001. Epub 2021 Aug 26.
9
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.
Nat Rev Immunol. 2021 Aug;21(8):475-484. doi: 10.1038/s41577-021-00578-z. Epub 2021 Jul 1.
10
Multi-generational SIR modeling: Determination of parameters, epidemiological forecasting and age-dependent vaccination policies.
Infect Dis Model. 2021;6:751-765. doi: 10.1016/j.idm.2021.05.003. Epub 2021 Jun 10.
本文引用的文献
1
Higher Viral Load Drives Infrequent Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Between Asymptomatic Residence Hall Roommates.
J Infect Dis. 2021 Oct 28;224(8):1316-1324. doi: 10.1093/infdis/jiab386.
2
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations.
Vaccine. 2020 Aug 10;38(36):5861-5876. doi: 10.1016/j.vaccine.2020.05.051. Epub 2020 Jun 10.
6
Guideline groups should make recommendations even if the evidence is considered insufficient.
CMAJ. 2020 Jan 13;192(2):E23-E24. doi: 10.1503/cmaj.190144.
7
Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance.
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12878-12886. doi: 10.1073/pnas.1717159115. Epub 2018 Dec 17.
8
Summary of the National Advisory Committee on Immunization's Update on the recommended human papillomavirus (HPV) vaccine immunization schedule.
Can Commun Dis Rep. 2015 Apr 20;41(Suppl 3):11-13. doi: 10.14745/ccdr.v41is3a03.
9
Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses.
PLoS Pathog. 2017 Jan 31;13(1):e1006194. doi: 10.1371/journal.ppat.1006194. eCollection 2017 Jan.
10
Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization.
Vaccine. 2010 Apr 19;28 Suppl 1:A58-63. doi: 10.1016/j.vaccine.2010.02.035.
Zotero 插件